Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 16/20 | 0.61 |
| ▸ | BCHE | P06276 | 15/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15819997 | 0.90 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL2058864 | 0.90 | PTGS1 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9690224 | 0.88 | ACHE (0.61) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9690289 | 0.87 | ACHE (0.63) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9312898 | 0.84 | PTGS1 (0.56) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9312837 | 0.84 | PTGS1 (0.55) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL7834529 | 0.83 | PTGS1 (0.57) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL30463821 | 0.82 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9253766 | 0.82 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL9313643 | 0.82 | PTGS1 (0.66) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128523-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2021-05-06 | — | — | US | claimed |
| US-20200206235-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2020-07-02 | — | — | US | claimed |
| EP-3672593-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| EP-3672592-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | Sulfateq B.V. (NL) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038360-A1 | 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICAMENT | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| WO-2019038361-A1 | MEDICAMENTS FOR THE TREATMENT OF VASOCONSTRICTION RELATED DISEASES OR DISORDERS | SULFATEQ B.V. (NL) | 2019-02-28 | — | — | WO | claimed |
| US-12156862-B2 | Medicaments for the treatment of vasoconstriction related diseases or disorders | SULFATEQ B.V. (NL) | 2024-12-03 | — | — | US | disclosed |
| US-12156862-B2 | Medicaments for the treatment of vasoconstriction related diseases or disorders | SULFATEQ B.V. (NL) | 2024-12-03 | — | — | US | disclosed |
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11730741-B2 | 6-chromanol derivatives for use as a medicament | SULFATEQ B.V. (NL) | 2023-08-22 | — | — | US | disclosed |
| US-11730741-B2 | 6-chromanol derivatives for use as a medicament | SULFATEQ B.V. (NL) | 2023-08-22 | — | — | US | disclosed |
| US-20230202997-A1 | CHROMANOL, QUINONE OR HYDROQUINONE COMPOUNDS FOR TREATMENT OF SEPSIS | SULFATEQ B.V. (NL) | 2023-06-29 | — | — | US | disclosed |
| EP-2220030-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9169196-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2013-10-31 | — | — | US | disclosed |
| US-8519001-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-7968746-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | PTGS1 2770/4885PTGS2 2594/4885CYP1A2 3899/4885 |
| US-20230202997-A1 | CHROMANOL, QUINONE OR HYDROQUINONE COMPOUNDS FOR TREATMENT OF SEPSIS | SQOR, SQLE, CYP11B2 | PTGS1 288/4885PTGS2 276/4885CYP1A2 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.